Creo Medical Limited – LSE:CREO.L
Creo Medical Limited stock price today
Creo Medical Limited stock price monthly change
Creo Medical Limited stock price quarterly change
Creo Medical Limited stock price yearly change
Creo Medical Limited key metrics
Market Cap | 79.13M |
Enterprise value | 3.28B |
P/E | -1.83 |
EV/Sales | 324763.25 |
EV/EBITDA | -205.59 |
Price/Sales | 3302.35 |
Price/Book | 0.54 |
PEG ratio | 0.08 |
EPS | -0.21 |
Revenue | 57.96M |
EBITDA | -49.49M |
Income | -48.63M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -138900.14% |
Oper. margin | -165544.83% |
Gross margin | 36.75% |
EBIT margin | -165544.83% |
EBITDA margin | -85.38% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCreo Medical Limited stock price history
Creo Medical Limited stock forecast
Creo Medical Limited financial statements
| Jun 2022 | 13.63M | -13.43M | -98.5% |
|---|---|---|---|
| Dec 2022 | 13.53M | -13.50M | -99.79% |
| Jun 2023 | 15.7M | -11.6M | -73.89% |
| Dec 2023 | 15.1M | -10.1M | -66.89% |
| 2027 | 95.19M | 6.00M | 6.31% |
|---|
Analysts Price target
Financials & Ratios estimates
| Jun 2022 | 87498000 | 26.39M | 30.17% |
|---|---|---|---|
| Dec 2022 | 75337000 | 25.93M | 34.42% |
| Jun 2023 | 88700000 | 19.7M | 22.21% |
| Dec 2023 | 76600000 | 16.8M | 21.93% |
| Jun 2022 | -15.81M | -1.93M | 226K |
|---|---|---|---|
| Dec 2022 | -9.17M | -4.09M | 296K |
| Jun 2023 | -14.9M | -17.4M | 30.6M |
| Dec 2023 | -6M | -1.6M | -800K |
Creo Medical Limited alternative data
| Aug 2023 | 284 |
|---|---|
| Sep 2023 | 284 |
| Oct 2023 | 279 |
| Nov 2023 | 279 |
| Dec 2023 | 279 |
| Jan 2024 | 279 |
| Feb 2024 | 279 |
| Mar 2024 | 279 |
| Apr 2024 | 279 |
| May 2024 | 279 |
| Jun 2024 | 279 |
| Jul 2024 | 279 |
Creo Medical Limited other data
| Insider | Compensation |
|---|---|
Mr. Craig Jonathan Gulliford (1971) Chief Executive Officer & Executive Director | $796,880 |
Prof. Christopher Paul Hancock (1968) Founder, Chief Technology Officer & Executive Director | $607,100 |
Mr. Richard John Rees ACA (1977) Chief Financial Officer, Company Sec. & Executive Director | $606,730 |
Mr. David Gerard Woods (1966) Chief Commercial Officer & Executive Director | $397,730 |
-
What's the price of Creo Medical Limited stock today?
One share of Creo Medical Limited stock can currently be purchased for approximately $149.
-
When is Creo Medical Limited's next earnings date?
Unfortunately, Creo Medical Limited's (CREO.L) next earnings date is currently unknown.
-
Does Creo Medical Limited pay dividends?
No, Creo Medical Limited does not pay dividends.
-
How much money does Creo Medical Limited make?
Creo Medical Limited has a market capitalization of 79.13M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 13.36% to 30.8M US dollars.
-
What is Creo Medical Limited's stock symbol?
Creo Medical Limited is traded on the LSE under the ticker symbol "CREO.L".
-
What is Creo Medical Limited's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Creo Medical Limited?
Shares of Creo Medical Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Creo Medical Limited's key executives?
Creo Medical Limited's management team includes the following people:
- Mr. Craig Jonathan Gulliford Chief Executive Officer & Executive Director(age: 54, pay: $796,880)
- Prof. Christopher Paul Hancock Founder, Chief Technology Officer & Executive Director(age: 57, pay: $607,100)
- Mr. Richard John Rees ACA Chief Financial Officer, Company Sec. & Executive Director(age: 48, pay: $606,730)
- Mr. David Gerard Woods Chief Commercial Officer & Executive Director(age: 59, pay: $397,730)
-
Is Creo Medical Limited founder-led company?
Yes, Creo Medical Limited is a company led by its founder Prof. Christopher Paul Hancock.
-
How many employees does Creo Medical Limited have?
As Jul 2024, Creo Medical Limited employs 279 workers.
-
When Creo Medical Limited went public?
Creo Medical Limited is publicly traded company for more then 8 years since IPO on 9 Dec 2016.
-
What is Creo Medical Limited's official website?
The official website for Creo Medical Limited is creomedical.com.
-
How can i contact Creo Medical Limited?
Creo Medical Limited can be reached via phone at +44 1291 606005.
Creo Medical Limited company profile:
Creo Medical Limited
creomedical.comLSE
278
Medical - Devices
Healthcare
Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
Chepstow, NP16 5UH
:
ISIN: GB00BZ1BLL44
CUSIP: G253HH102
